Angiogenic Factor (AF) Plays A Crucial Role in Blood Vessel Development

Target Name: Angiogenic Factor

NCBI ID: P40934

Angiogenic Factor

Other Name(s): Angiogenic Factor

Angiogenic Factor (AF) Plays A Crucial Role in Blood Vessel Development

Angiogenic Factor (nonspecified subtype), also known as Angiogenic Factor (AF), is a protein that plays a crucial role in the development and maintenance of blood vessels. It is a potent regulator of angiogenesis, which is the process by which new blood vessels grow and function. AF is responsible for promoting the growth and proliferation of blood vessels, as well as guiding their branching and formation.

AF is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, and blood vessels. It is characterized by a long N-terminus that is involved in its cytoplasmic localization and by a C-terminus that is involved in its extracellular interactions.

One of the most significant functions of AF is its ability to promote the formation of new blood vessels. AF has been shown to play a key role in the development of new blood vessels in various organisms, including humans. AF promotes the growth of blood vessels in response to various signaling pathways, including the TGF-β pathway and the Wnt pathway.

In addition to its role in blood vessel development, AF is also involved in the regulation of angiogenesis in various tissues. For example, AF has been shown to play a critical role in the development of new blood vessels in the brain, which is critical for the proper functioning of the central nervous system.

Another function of AF is its ability to modulate the diameter of blood vessels. AF has been shown to regulate the elastin-to-hyaluronic acid (E-tH) ratio, which is a critical determinant of blood vessel diameter. The E-tH ratio is a measure of the amount of extracellular matrix protein in the surrounding tissue that can be detected in the intravascular space. AF has been shown to increase the E-tH ratio, which promotes blood vessel dilation and increases blood flow to the target tissue.

In addition to its role in blood vessel development and regulation, AF is also involved in the regulation of angiogenesis in various signaling pathways. For example, AF has been shown to be involved in the regulation of theNotch signaling pathway, which is a critical pathway involved in the development of new blood vessels.

Despite its significant role in the regulation of angiogenesis, the precise mechanism by which AF promotes blood vessel growth and formation is not well understood. However, it is thought to involve a complex interplay of various signaling pathways, including TGF-β, Wnt, and Notch.

One potential drug target for AF is the inhibition of its activity. The use of AF inhibitors has been shown to be effective in various models of Angiogenesis, including the treatment of cancer, cardiovascular disease, and neurological disorders.

In conclusion, Angiogenic Factor (AF) is a protein that plays a critical role in the development and maintenance of blood vessels. It is a potent regulator of angiogenesis, and its activity is modulated by various signaling pathways. The inhibition of AF activity has been shown to be effective in various models of Angiogenesis, and its potential as a drug target makes it an attractive target for the development of new treatments for various cardiovascular and neurological disorders.

Protein Name: Angiogenic Factor (nonspecified Subtype)

The "Angiogenic Factor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Angiogenic Factor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets